Evidence map›Paper›PMID 38327103›Full record

ArticleCancer science2024

Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.

Koji Izutsu, Kumi Ubukawa, Takanobu Morishita, Yasushi Onishi, Kenichi Ishizawa, Yosuke Fujii, Nobuyuki Kimura, Miyuu Yokochi, Tomoki Naoe

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9129-8057
Kumi UbukawaDepartment of Hematology, Nephrology and Rheumatology, Akita University Hospital, Akita, Japan.
Takanobu MorishitaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Miyagi, Japan.
Kenichi IshizawaDepartment of Internal Medicine III, Yamagata University Hospital, Yamagata, Japan.
Yosuke FujiiPfizer R&D Japan, Tokyo, Japan.
Nobuyuki KimuraPfizer R&D Japan, Tokyo, Japan.
Miyuu YokochiPfizer R&D Japan, Tokyo, Japan.
Tomoki NaoeNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Pfizer (Japan) · JPAkita University Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPNational Hospital Organization · JPTohoku University Hospital · JPTokyo National Hospital · JPYamagata University Hospital · JP

Funding

Pfizer
6 · The paper itself

Abstract

Glasdegib is a potent, selective, oral inhibitor of the hedgehog signaling pathway. In this phase I study, previously untreated Japanese patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes were treated with glasdegib (100 mg once daily) combinations: low-dose cytarabine (20 mg twice daily; cohort 1, n = 6; expansion cohort, n = 15); daunorubicin and cytarabine (60 mg/m

Indexed as

BenzimidazolesLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPhenylurea CompoundsThrombocytopeniaAntineoplastic Combined Chemotherapy ProtocolsCytarabineHedgehog ProteinsHumansJapanBenzimidazolesCytarabineglasdegibHedgehog ProteinsPhenylurea Compoundsacute myeloid leukemiaclinical trialglasdegibmyelodysplastic syndromesnewly diagnosed

Identifiers

PMID38327103
PMCPMC11006982
OpenAlexW4391635339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.